• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
73,524.26 -719.08
( -0.97%)
Global Indices
Nasdaq
50,812.84 -74.94
(-0.15%)
Dow Jones
7,426.81 22.07
(0.30%)
Hang Seng
63,697.20 -2,890.92
(-4.34%)
Nikkei 225
10,368.25 0.20
(0.00%)
Forex
USD-INR
95.73 0.01
(0.01%)
EUR-INR
111.21 0.07
(0.06%)
GBP-INR
128.58 -0.06
(-0.05%)
JPY-INR
0.60 0.00
(0.01%)

EQUITY - MARKET SCREENER

ICICI Bank Ltd
Industry :  Banks - Private Sector
BSE Code
ISIN Demat
Book Value()
532174
INE090A01021
461.5408182
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
ICICIBANK
18.05
905074.77
EPS(TTM)
Face Value()
Div & Yield %
69.93
2
0.95
 

Supriya Lifescience's manufacturing unit clears USFDA inspection
Apr 22,2026
Supriya Lifescience announced that the U.S. Food and Drug Administration (US FDA) conducted an inspection at the Company's manufacturing facility located at Lote, Parshuram Industrial Area, Maharashtra, India, from 2 February 2026 to 6 February 2026.

The inspection concluded with the issuance of a Form 483 containing one (1) minor observation. The Company has adequately addressed the observation and has received the Establishment Inspection Report (EIR) indicating “Voluntary Action Indicated (VAI)”, signifying a successful completion of the inspection.